FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4327684313> ?p ?o ?g. }

• W4327684313 endingPage "493" @default.
• W4327684313 startingPage "488" @default.
• W4327684313 abstract "To estimate the health utilities and quality-adjusted life years (QALYs) in patients with amyotrophic lateral sclerosis (ALS) receiving reldesemtiv versus placebo in FORTITUDE-ALS.We performed a post hoc analysis of clinical trial data from FORTITUDE-ALS (NCT03160898). This Phase IIb, double-blind, randomized, dose-ranging, placebo-controlled, parallel-group, 12-week trial evaluated reldesemtiv in patients with ALS. Health utilities from the five-level version of the EuroQol five-dimensional questionnaire (EQ-5D-5L) were estimated using ALS Functional Rating Scale-Revised (ALSFRS-R) scores collected during the trial. QALYs were estimated using the area under the curve method.The full analysis set consisted of 456 patients (reldesemtiv n = 342, placebo n = 114), who received at least one dose of the double-blind study drug, and had ALSFRS-R assessed at baseline and at least one post-baseline assessment. The difference in EQ-5D-5L utility least-squares (LS) mean change from baseline to week 12 for reldesemtiv versus placebo, adjusted for baseline values, was statistically significant (0.03, 95% confidence interval [CI]: 0.01, 0.05; p = .0008). The incremental QALY of reldesemtiv versus placebo adjusted for baseline utility values showed a modest, but statistically significant, difference (0.004, 95% CI: 0.001, 0.007; p = .0058).This post hoc analysis of FORTITUDE-ALS suggests that reldesemtiv showed a modest but significant benefit in health utilities and QALYs compared with placebo. Future long-term studies that include direct collection of EQ-5D-5L data will be needed to confirm our findings.NCT03160898." @default.
• W4327684313 created "2023-03-18" @default.
• W4327684313 creator A5004383772 @default.
• W4327684313 creator A5014335916 @default.
• W4327684313 creator A5020115938 @default.
• W4327684313 creator A5022326820 @default.
• W4327684313 creator A5030730290 @default.
• W4327684313 creator A5036838632 @default.
• W4327684313 creator A5040375788 @default.
• W4327684313 creator A5052880954 @default.
• W4327684313 creator A5063229609 @default.
• W4327684313 creator A5065006726 @default.
• W4327684313 creator A5070376982 @default.
• W4327684313 creator A5073608742 @default.
• W4327684313 creator A5082774982 @default.
• W4327684313 creator A5084278566 @default.
• W4327684313 creator A5090628289 @default.
• W4327684313 date "2023-03-31" @default.
• W4327684313 modified "2023-10-02" @default.
• W4327684313 title "Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving <i>reldesemtiv</i> or placebo in FORTITUDE-ALS" @default.
• W4327684313 cites W1973830088 @default.
• W4327684313 cites W1992926914 @default.
• W4327684313 cites W1996519676 @default.
• W4327684313 cites W2028067695 @default.
• W4327684313 cites W2108381339 @default.
• W4327684313 cites W2118249259 @default.
• W4327684313 cites W2165533349 @default.
• W4327684313 cites W2259797591 @default.
• W4327684313 cites W2343426002 @default.
• W4327684313 cites W2587800700 @default.
• W4327684313 cites W2794076515 @default.
• W4327684313 cites W2883181144 @default.
• W4327684313 cites W2907219364 @default.
• W4327684313 cites W3048642956 @default.
• W4327684313 cites W3088717396 @default.
• W4327684313 cites W4206387730 @default.
• W4327684313 cites W4223507637 @default.
• W4327684313 cites W4252979096 @default.
• W4327684313 doi "https://doi.org/10.1080/13696998.2023.2192588" @default.
• W4327684313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36930042" @default.
• W4327684313 hasPublicationYear "2023" @default.
• W4327684313 type Work @default.
• W4327684313 citedByCount "0" @default.
• W4327684313 crossrefType "journal-article" @default.
• W4327684313 hasAuthorship W4327684313A5004383772 @default.
• W4327684313 hasAuthorship W4327684313A5014335916 @default.
• W4327684313 hasAuthorship W4327684313A5020115938 @default.
• W4327684313 hasAuthorship W4327684313A5022326820 @default.
• W4327684313 hasAuthorship W4327684313A5030730290 @default.
• W4327684313 hasAuthorship W4327684313A5036838632 @default.
• W4327684313 hasAuthorship W4327684313A5040375788 @default.
• W4327684313 hasAuthorship W4327684313A5052880954 @default.
• W4327684313 hasAuthorship W4327684313A5063229609 @default.
• W4327684313 hasAuthorship W4327684313A5065006726 @default.
• W4327684313 hasAuthorship W4327684313A5070376982 @default.
• W4327684313 hasAuthorship W4327684313A5073608742 @default.
• W4327684313 hasAuthorship W4327684313A5082774982 @default.
• W4327684313 hasAuthorship W4327684313A5084278566 @default.
• W4327684313 hasAuthorship W4327684313A5090628289 @default.
• W4327684313 hasBestOaLocation W43276843131 @default.
• W4327684313 hasConcept C112930515 @default.
• W4327684313 hasConcept C126322002 @default.
• W4327684313 hasConcept C142724271 @default.
• W4327684313 hasConcept C159110408 @default.
• W4327684313 hasConcept C168563851 @default.
• W4327684313 hasConcept C1862650 @default.
• W4327684313 hasConcept C204787440 @default.
• W4327684313 hasConcept C27081682 @default.
• W4327684313 hasConcept C2779134260 @default.
• W4327684313 hasConcept C2779951463 @default.
• W4327684313 hasConcept C2780596555 @default.
• W4327684313 hasConcept C2992886853 @default.
• W4327684313 hasConcept C3019080777 @default.
• W4327684313 hasConcept C44249647 @default.
• W4327684313 hasConcept C535046627 @default.
• W4327684313 hasConcept C64332521 @default.
• W4327684313 hasConcept C67761136 @default.
• W4327684313 hasConcept C71924100 @default.
• W4327684313 hasConceptScore W4327684313C112930515 @default.
• W4327684313 hasConceptScore W4327684313C126322002 @default.
• W4327684313 hasConceptScore W4327684313C142724271 @default.
• W4327684313 hasConceptScore W4327684313C159110408 @default.
• W4327684313 hasConceptScore W4327684313C168563851 @default.
• W4327684313 hasConceptScore W4327684313C1862650 @default.
• W4327684313 hasConceptScore W4327684313C204787440 @default.
• W4327684313 hasConceptScore W4327684313C27081682 @default.
• W4327684313 hasConceptScore W4327684313C2779134260 @default.
• W4327684313 hasConceptScore W4327684313C2779951463 @default.
• W4327684313 hasConceptScore W4327684313C2780596555 @default.
• W4327684313 hasConceptScore W4327684313C2992886853 @default.
• W4327684313 hasConceptScore W4327684313C3019080777 @default.
• W4327684313 hasConceptScore W4327684313C44249647 @default.
• W4327684313 hasConceptScore W4327684313C535046627 @default.
• W4327684313 hasConceptScore W4327684313C64332521 @default.
• W4327684313 hasConceptScore W4327684313C67761136 @default.
• W4327684313 hasConceptScore W4327684313C71924100 @default.
• W4327684313 hasFunder F4320315432 @default.
• W4327684313 hasIssue "1" @default.

• next